RBCL (RBC Life Sciences) 1-Year Sharpe Ratio: 1.94 (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is RBC Life Sciences 1-Year Sharpe Ratio?

RBC Life Sciences RBCL +0.14% 1-Year Sharpe Ratio is 1.94 as of Jul. 30, 2026.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-30), RBC Life Sciences's 1-Year Sharpe Ratio is 1.94.

RBC Life Sciences  (OTCPK:RBCL) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

RBC Life Sciences 1-Year Sharpe Ratio Related Terms

RBCL vs SKVI, TISUQ, TECR: 1-Year Sharpe Ratio Comparison

For the Household & Personal Products subindustry, RBC Life Sciences's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RBC Life Sciences 1-Year Sharpe Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, RBC Life Sciences's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where RBC Life Sciences's 1-Year Sharpe Ratio falls into.


RBC Life Sciences 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 1.94 mean?
RBC Life Sciences (RBCL) has a 1-Year Sharpe Ratio of 1.94 as of Jul. 30, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for RBC Life Sciences and its competitors.
Is RBC Life Sciences' 1-Year Sharpe Ratio too high?
RBC Life Sciences' current 1-Year Sharpe Ratio is 1.94.
How does RBC Life Sciences' 1-Year Sharpe Ratio compare to SKVI and TISUQ?
RBC Life Sciences' 1-Year Sharpe Ratio of 1.94 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Consumer Packaged Goods company?
A good 1-Year Sharpe Ratio depends on the Consumer Packaged Goods industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for RBC Life Sciences and its competitors. RBC Life Sciences's current 1-Year Sharpe Ratio is 1.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RBC Life Sciences stock overvalued right now?
RBC Life Sciences (RBCL) has a current 1-Year Sharpe Ratio of 1.94. The current 1-Year Sharpe Ratio is 1.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For RBC Life Sciences (RBCL), the current 1-Year Sharpe Ratio is 1.94 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RBC Life Sciences Business Description

Address 2301 Crown Court, Irving, TX, USA, 75038
RBC Life Sciences Inc, through its subsidiaries, is engaged in marketing and distribution of nutritional supplements and personal care products. Its products include herbal formulas, vitamins, minerals, antioxidants, and skin, hair and body care products. It also markets its Nutritional Products in certain international markets through license arrangements. In addition to its Nutritional Products, the company also markets a line of wound care products under the MPM Medical brand name through a U.S. subsidiary.